股市必读：罗欣药业（002793）10月27日主力资金净流入330.53万元

Summary of Key Points Core Viewpoint - 罗欣药业's recent financial disclosures indicate a mixed performance in non-recurring gains and losses, with significant fluctuations over the past three years, highlighting the company's reliance on non-operational income sources [1][2]. Group 1: Financial Performance - As of October 27, 2025, 罗欣药业's stock closed at 5.31 yuan, down 0.75%, with a trading volume of 254,700 shares and a turnover of 136 million yuan [1]. - The net non-recurring gains and losses for 罗欣药业 from 2022 to the first nine months of 2025 were reported as 215,423,150.70 yuan, -22,285,473.56 yuan, -197,375,374.58 yuan, and 18,008,575.68 yuan respectively [1]. - The significant non-recurring gain in 2022 was primarily due to non-current asset disposal, amounting to 136,264,318.65 yuan, while a loss of 213,130,913.80 yuan was recorded in 2024 due to fair value changes related to the disposal of 上药罗欣 [1]. Group 2: Fund Utilization - 罗欣药业's previous fundraising efforts totaled 663,566.00 million yuan, fully utilized for acquiring a 99.65476% stake in 山东罗欣药业 [2][3]. - The asset performance post-acquisition showed a net profit of 56,450.69 million yuan in 2019, but fell short of commitments in 2020 and 2021, leading to the cancellation of 371,334,114 shares as compensation [2]. - The total assets of 罗欣药业 decreased from 721,226.54 million yuan at the end of 2019 to 497,240.24 million yuan by the end of 2024 [2].